These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 16092048

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Increased glutathionylated hemoglobin (HbSSG) in type 2 diabetes subjects with microangiopathy.
    Sampathkumar R, Balasubramanyam M, Sudarslal S, Rema M, Mohan V, Balaram P.
    Clin Biochem; 2005 Oct; 38(10):892-9. PubMed ID: 16051210
    [Abstract] [Full Text] [Related]

  • 6. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
    Busch M, Franke S, Wolf G, Brandstädt A, Ott U, Gerth J, Hunsicker LG, Stein G, Collaborative Study Group.
    Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
    [Abstract] [Full Text] [Related]

  • 7. Serum total and high molecular weight adiponectin levels are correlated with the severity of diabetic retinopathy and nephropathy.
    Kato K, Osawa H, Ochi M, Kusunoki Y, Ebisui O, Ohno K, Ohashi J, Shimizu I, Fujii Y, Tanimoto M, Makino H.
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):442-9. PubMed ID: 17970779
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Increased serum levels of advanced glycation end products in NIDDM patients with diabetic complications.
    Ono Y, Aoki S, Ohnishi K, Yasuda T, Kawano K, Tsukada Y.
    Diabetes Care; 1998 Jun; 21(6):1027. PubMed ID: 9614627
    [No Abstract] [Full Text] [Related]

  • 11. Soluble LDL-immune complexes in type 2 diabetes and vascular disease.
    Turk Z, Sesto M, Skodlar J, Ferencak G, Turk N, Stavljenić-Rukavina A.
    Horm Metab Res; 2002 Apr; 34(4):196-201. PubMed ID: 11987029
    [Abstract] [Full Text] [Related]

  • 12. Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications.
    Chiodini I, Adda G, Scillitani A, Coletti F, Morelli V, Di Lembo S, Epaminonda P, Masserini B, Beck-Peccoz P, Orsi E, Ambrosi B, Arosio M.
    Diabetes Care; 2007 Jan; 30(1):83-8. PubMed ID: 17192338
    [Abstract] [Full Text] [Related]

  • 13. Immunochemical quantification of crossline as a fluorescent advanced glycation endproduct in erythrocyte membrane proteins from diabetic patients with or without retinopathy.
    Yamaguchi M, Nakamura N, Nakano K, Kitagawa Y, Shigeta H, Hasegawa G, Ienaga K, Nakamura K, Nakazawa Y, Fukui I, Obayashi H, Kondo M.
    Diabet Med; 1998 Jun; 15(6):458-62. PubMed ID: 9632118
    [Abstract] [Full Text] [Related]

  • 14. Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease.
    Nishizawa Y, Koyama H.
    J Ren Nutr; 2008 Jan; 18(1):76-82. PubMed ID: 18089449
    [Abstract] [Full Text] [Related]

  • 15. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
    Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T.
    Int J Clin Pharmacol Res; 2003 Jan; 23(4):129-34. PubMed ID: 15224502
    [Abstract] [Full Text] [Related]

  • 16. Products of advanced glycation in patients with type 2 diabetes and vascular disease.
    Turk Z, Sesto M, Skodlar J, Ferencak G, Pokupec R, Turk N, Stavljenić-Rukavina A.
    Ann Clin Biochem; 2003 Sep; 40(Pt 5):552-9. PubMed ID: 14503994
    [Abstract] [Full Text] [Related]

  • 17. [Changes in microcirculation and selected laboratory parameters in the early stages of diabetic microangiopathy].
    Skrha J, Prázný M, Kvasnicka J, Kalvodová B.
    Cas Lek Cesk; 2001 Jun 21; 140(12):370-4. PubMed ID: 11503186
    [Abstract] [Full Text] [Related]

  • 18. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.
    Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi T.
    Diabetes Metab Res Rev; 2008 Feb 21; 24(2):109-14. PubMed ID: 17694504
    [Abstract] [Full Text] [Related]

  • 19. Advanced glycosylation end products in patients with diabetic nephropathy.
    Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H.
    N Engl J Med; 1991 Sep 19; 325(12):836-42. PubMed ID: 1875967
    [Abstract] [Full Text] [Related]

  • 20. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy.
    Zhou H, Tan KC, Shiu SW, Wong Y.
    Nephrol Dial Transplant; 2008 Mar 19; 23(3):927-33. PubMed ID: 18065800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.